Frequency and Antibiotic Resistance of Hybrid Entroaggregative/Uropathogenic Escherichia coli Isolated from Patients Hospitalized in Isfahan, Iran

Document Type : Original Research

Authors
T. Alipour 1
S. Farzi 2
A. Emamie 3
A. Darbandi 4
1 Department of Bacteriology and Virology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
2 Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran
3 Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
4 Department of Microbiology, School of Medicine and Microbial Biotechnology Research Centre, Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran, Iran.
10.52547/iem.7.3.207
Abstract
Backgrounds: This study aimed to analyse hybrid Entroaggregative/Uropathogenic Escherichia coli (EAEC/UPEC) isolates. To do so, the antibiotic resistance pattern and virulence genes were investigated in E. coli strains isolated from clinical specimens of patients hospitalized in Isfahan, Iran.

Materials & Methods: Disc diffusion method was used to determine the antibiotic susceptibility pattern of EAEC/UPEC isolates. Also, virulence determinants of these isolates were determinated by singleplex and multiplex PCR.

Findings: Overall, a total of 148 E. coli isolates were collected, of which 12 (8.1%) isolates were hybrid EAEC/UPEC strains, then antibiotic susceptibility examination was operated on these strains. The higest antibiotic resistance rate was related to ofloxacin (42%), followed by trimethoprim-sulfamethoxazole (41%), ceftriaxone and cefepime (33%), and cefoxitin (17%). All the isolates showed susceptibility to fosfomycin.

Conclusion: According to the current study, since resistance to fluoroquinolones has increased in hybrid strains, monitoring the drug susceptibility of hybrid strains seems critical in Iran. Fosfomycin is considered to be the drug of choise for infections caused by multidrug-resistant (MDR) Gram-positive and Gram-negative bacteria. Fortunately, 100% of the strains were sensitive to fosfomycin.

Keywords

Subjects

1- Soltani S, Emamie AD, Dastranj M, Farahani A, Davoodabadi A, Mohajeri P. Role of toxins of uropathogenic Escherichia coli in development of urinary tract infection. Journal of Pharmaceutical Research International. 2018:1-11.
2- Santos ACdM, Santos F, Silva RM, Gomes TAT. Diversity of Hybrid-and Hetero-Pathogenic Escherichia coli and Their Potential Implication in More Severe Diseases. Front Cell Infect Microbiol. 2020; 10:339
3- Miri ST, Dashti A, Mostaan S, Kazemi F, Bouzari S. Identification of different Escherichia coli pathotypes in north and north-west provinces of Iran. Iran J Microbiol. 2017;9(1):33.
4- B.H.jensen,K.E.Olsen, C.Struve,K.A. Krogfelt, A.M. Petersen, Epidemiology and clinical manifestation of enteroaggregative Escherichia coli, Clin Microbiol Rev. 27(3) (2014) 614-630.
5- Momtaz H, et al. Uropathogenic Escherichia coli in Iran: serogroup distributions, virulence factors and antimicrobial resistance properties. Ann Clin Microbiol Antimicrob. 2013;12(1):8
6- Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev. 1991;4(1):80–128.
7- Soto S, et al. Prevalence of the set-1B and astA genes encoding enterotoxins in uropathogenic Escherichia coli clinical isolates. Microb Pathog. 2009;47(6):305–7.
8- Bauer RJ, et al. Molecular epidemiology of 3 putative virulence genes for Escherichia coli urinary tract infection–usp, iha, and iroNE. coli. J Infect Dis. 2002;185(10):1521–4.
9- Jahandeh N, et al. Uropathogenic Escherichia coli virulence genes: invaluable approaches for designing DNA microarray probes. Cent European J Urol. 2015;68(4):452.
10- Farshad, S., et al., Microbial susceptibility, virulence factors, and plasmid profiles of uropathogenic Escherichia coli strains isolated from children in Jahrom, Iran. Arch Iran Med (AIM), 2012. 15(5).
11- Tajbakhsh E, et al. Prevalence of class 1 and 2 integrons in multi-drug resistant Escherichia coli isolated from aquaculture water in Chaharmahal Va Bakhtiari province, Iran. Ann Clin Microbiol Antimicrob. 2015;14(1):37
12- Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–33
13- Blair JMA, et al. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2014;13:42
14- Boll EJ, Struve C, Boisen N, Olesen B, Stahlhut SG, Krogfelt KA. Role of enteroaggregative Escherichia coli virulence factors in uropathogenesis. Infect Immun. 2013;81(4):1164-71.
15- Mohebi S, Hossieni Nave H, Norouzi A, Kandehkar Gharaman M, Taati Moghadam M. Detection of extended spectrum beta lactamases on class I integron in Escherichia coli isolated from clinical samples. Journal of Mazandaran University of Medical Sciences. 2016;26(138):66-76.
16- Toval F, Köhler C-D, Vogel U, Wagenlehner F, Mellmann A, Fruth A, et al. Characterization of Escherichia coli isolates from hospital inpatients or outpatients with urinary tract infection. J Clin Microbiol. 2014;52(2):407-18.
17- Santos ACdM, Santos F, Silva RM, Gomes TAT. Diversity of Hybrid-and Hetero-Pathogenic Escherichia coli and Their Potential Implication in More Severe Diseases. Front Cell Infect Microbiol. 2020;10:339.
18- Darbandi A, Owila P, Bouzari S, Saderi H. Diarrheagenic Escherichia coli pathotypes frequency in Khuzestan province of Iran. Iran j Microbiol 2016; 8:352-358.
19- Shahbazi S, Karam MRA, Habibi M, Talebi A, Bouzari S. Distribution of extended-spectrum β-lactam, quinolone and carbapenem resistance genes, and genetic diversity among uropathogenic Escherichia coli isolates in Tehran, Iran. J Glob Antimicrob Resist. 2018;14:118-25.
20- Nave HH, Mansouri S, Moghadam MT, Moradi M. Virulence gene profile and multilocus variable-number tandem-repeat analysis (MLVA) of enteroinvasive Escherichia coli (EIEC) isolates from patients with diarrhea in Kerman, Iran. Jundishapur J Microbiol. 2016;9(6):1-6.
21- Kot B. Antibiotic resistance among uropathogenic Escherichia coli. Pol J Microbiol. 2019;68(4):403.
22- Alikhani MY, Hashemi SH, Aslani MM, Farajnia S. Prevalence and antibiotic resistance patterns of diarrheagenic Escherichia coli isolated from adolescents and adult in Hamedan,Western Iran. Iran J microbial 2013; 5:42-47.
23- Bouzari S, Jafari A, Zarepoor M.Distribution of genes encoding toxins and antibiotic resistance patterns in diarrhoeagenic Escherichia coli isolates in Tehran. East Mediterr Health J. 2007; 13:287-293.
24- C. Performance standards for antimicrobial susceptibility testing. 30th Edn. CLSI supplement M100. Wayne: Clinical and Laboratory Standards Institute (2020).
25- Kot B. Antibiotic resistance among uropathogenic Escherichia coli. Polish journal of microbiology. 2019;68(4):403.
26- Najafi N, Alikhani A, Babamahmoudi F, et al. Increased cefepime MIC for enterobacteriacaeclinical isolates. Caspian J Intern Med. 2013 4(2):654-7.
27- Farajnia S, Alikhani MY, Ghotaslou R, et al. Causative agents and antimicrobial susceptibilities of urinary tract infections in the northwest of Iran. IntJ Infect Dis. 2009.13(2):140-4.
28- Adib N, Ghanbarpour R, Solatzadeh H, et al. Antibiotic resistance profile and virulence genes of uropathogenic Escherichia coli isolates in relation to phylogeny. Trop Biomed. 2014; 31(1):17-25.
29- Alikhani A,Babamahmoodi F,Foroutan Aliza-degan L, et al (2015). Minimal inhibitory concentration of microorganisms causing surgical site infection in referral hospitals in North of Iran, 2011-2012. Caspian J Intern Med, 6(1):34-9.
30- Park YS, Adams-Haduch JM, Shutt KA, et al. Clinical and Microbiologic Characteristics of Cephalosporin-Resistant Escherichia coli in Three Centers in the United States. Antimicrob Agents Chemother, 2012; 56(4):1870-6.
31- Hawser S, Bouchillon S, Lascols C, et al. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009). Clin Microbiol Infect, 2012; 18(3):253-9.
32- Bantar C, Famiglietti A, Goldberg M. Three-year surveillance study of nosocomial bacterial resistance in Argentina. Int J Infect Dis, 2000; 4(2):85-90.
33- Shakya P, Barrett P, Diwan V, et al. Antibiotic resistance among Escherichia coli isolates from stool samples of children aged 3 to 14 years from Ujjain, India. BMC Infect Dis, 2013; 13:477.
34- Samal SK, Khuntia HK, Nanda PK, Satapathy CS, Nayak SR, Sarangi AK, et al. Incidence of bacterial enteropathogens among hospitalized diarrhea patients from Orissa, India. Jpn J Infect Dis 2008; 61: 350-355.
35- Vaishnavi C, Kaur S. The epidemiological and resistogram patterns of enteropathogenic and enterotoxigenic Escherichia coli isolated from diarrhoeal stools in a north Indian hospital. Trop Gastroenterol 2003; 24: 70-72.
36- Falagas, M.E.; Kastoris, A.C.; Karageorgopoulos, D.E.; Rafailidis, P.I. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting gram-negative bacilli: A systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009,34,111-120.
37- Neuner, E.A.; Sekeres, J.; Hall, G.S.; van Duin, D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 2012, 56, 5744–5748.
38- Falagas, M.E.; Kastoris, A.C.; Kapaskelis, A.M.; Karageorgopoulos, D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: A systematic review. Lancet Infect Dis. 2010, 10,43–50.
39- Bahramian A, Eslami G, Hashemi A, Tabibi A, Heidary M. Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases. Acta microbiologica et immunologica Hungarica. 2018;65(1):15-25.
40- Malekpour Kolbadinezhad. S, Fozouni L. Molecular Monitoring of Fosfomycin Resistance in Escherichia coli Strains Isolated from Patients with Urinary Catheters in north-east of Iran. Journal of Medical Microbiology and Infectious Diseases. 2018;6(4):112-7.
41- Cottell JL, Webber MA. Experiences in fosfomycin susceptibility testing and resistance mechanism determination in Escherichia coli from urinary tract infections in the U.K. Journal of medical microbiology. 2019;68(2):161-8.
42- Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgraduate medicine. 2017;129(2):242-58.
Infection Epidemiology and Microbiology
Volume 7, Issue 3
July 2021
Pages 207-214